证券代码：870199 证券简称：倍益康 公告编号：2025-049 四川千里倍益康医疗科技股份有限公司 第三届监事会第二十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序等方面符合《公司法》等法律、行政 法规、部门规章、规范性文件和《公司章程》《监事会议事规则》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于补充审议日常性关联交易的议案》 1.议案内容： 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席王刚 因公司于 2024 年 5 月 21 日转让控股子公司东莞市倍露康电子科技有限公司 （以下简称"倍露康"）21%的股权后，公司仅持有倍露康 30%股权，导致倍露康 不再纳入公司合并报表范围。因此，公司 2024 年 5 月 21 日至 2024 年 12 月 31 本议案不涉及回避表决。 本议案无需提交股东会审议 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-048 四川千里倍益康医疗科技股份有限公司 第三届董事会第二十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 28 日 2.会议召开地点：公司会议室 5.会议主持人：董事长张文 6.会议列席人员：全体监事和高级管理人员 7.召开情况合法、合规、合章程性说明： 具体内容详见公司于 2025 年 5 月 30 日在北京证券交易所信息披露平台 （http://www.bse.cn/）披露的《关于补充确认关联交易的公告》（公告编号： 2025-050）。 本次会议的召集、召开、议案审议程序等方面符合《公司法》等法律、行政 法规、部门规章、规范性文件和《公司章程》《董事会议事规则》的规定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 二、议案审议情况 （一）审议通过《关于补充审议日常性关联交易的议案》 1.议案内容： 因公 ...

Group 1: Investor Relations Activities - The company conducted a specific investor survey and media interviews on May 29, 2025, attended by representatives from Galaxy Securities, Rongxian Huijin Fund, and China Securities Journal [3][4] Group 2: Sales and Market Performance - The overseas market sales have remained stable this year, with the portable pneumatic massage system receiving widespread attention and positive feedback from global customers [4] - The company plans to enhance the market promotion of the compression boots, leveraging existing sales channels in the massage gun sector [4] Group 3: Product Innovation and Development - Future product innovation strategies include increased investment in "medical + consumer" resources and a focus on rehabilitation medical technology [5] - The company aims to develop more products suitable for the elderly, addressing the growing health needs of this demographic [5] Group 4: Profitability and Product Structure - The gross margin for rehabilitation medical products is 47.86%, while rehabilitation technology products have a gross margin of 37.11%, indicating room for improvement [6] - The company is actively developing new products to enrich its product line [6] Group 5: Investment Projects and Production Capacity - The Chengdu Intelligent Manufacturing Production Base is on track for completion, expected to be accepted in July 2025, which will enhance production capacity and efficiency [7] - The introduction of advanced production equipment and automated lines will lower production costs and improve overall profitability [7] Group 6: Research and Development - R&D expenses are determined by various factors, including company strategy and market demand, rather than a fixed threshold [9] - New products such as the medium-frequency therapy device and portable oxygen machine have received regulatory approval, while others are in development [9]

Market Overview - The Shanghai Composite Index closed at 3346.84 points, slightly above the half-year line, with a change of -0.05% [1] - The total trading volume of A-shares reached 10338.72 billion yuan [1] Stocks Performance - A total of 231 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Junyao Health: 9.37% - Guangsha Environmental Energy: 8.42% - Longzhou Co., Ltd.: 7.79% [1] - Stocks with lower deviation rates that just crossed the half-year line include: - Wantai Biological Pharmacy: 6.51% - Huatai Securities: 6.40% - Jiayuan Technology: 6.17% [1] Notable Stocks - The top three stocks with the highest daily increase: - Junyao Health: +10.08% - Guangsha Environmental Energy: +9.23% - Longzhou Co., Ltd.: +10.02% [1] - The trading turnover rates for these stocks were also significant, with Guangsha Environmental Energy at 7.92% and Longzhou Co., Ltd. at 8.30% [1] Additional Stocks Data - Other notable stocks with their respective performance: - Huachang Communication: +19.99% with a turnover rate of 12.90% - Huali Technology: +7.44% with a turnover rate of 13.05% [1] - The data indicates a healthy trading environment with several stocks showing strong performance above the half-year line [1]

证券代码：870199 证券简称：倍益康 公告编号：2025-047 （一） 对公司财务状况和经营成果的影响 本次获证是继公司 2025 年 4 月取得干扰电治疗仪医疗器械注册证后，取 得的又一个 II 类医疗器械产品注册证。该产品可以和公司现有的肌电生物反 馈仪、盆底康复仪主机配套使用，满足患者需求，为公司开辟新的收入来源。 在财务方面，随着公司阴道电极以及在研中的直肠电极、理疗电极等配套 耗材的相继推出，由于耗材的复购特性，有望提升公司盈利能力，优化财务状 况。 四川千里倍益康医疗科技股份有限公司 关于产品取得医疗器械注册证的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 在研产品取得阶段性成果情况 在研产品名称：阴道电极 四川千里倍益康医疗科技股份有限公司（以下简称"公司"）在研产品于 近期取得四川省药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序 | 产品 | 证书编号 | 注册 | | | 证书有效期 | | | 适用范围 | | --- | --- | --- | ...

证券代码：870199 证券简称：倍益康 公告编号：2025-045 四川千里倍益康医疗科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 8 日 2.会议召开地点：四川千里倍益康医疗科技股份有限公司会议室 3.会议召开方式：现场投票、网络投票 4.会议召集人：董事会 5.会议主持人：董事长张文先生 6.召开情况合法、合规、合章程性说明： 本次股东会的召集及召开时间、方式、召集人及主持人符合《公司法》《公 司章程》的规定，审议事项合法、完备。 （二）会议出席情况 出席和授权出席本次股东会的股东共 10 人，持有表决权的股份总数 51,160,200 股，占公司有表决权股份总数的 75.11%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、监事、高级管理人员出席或列席股东会情况 1.公司在任董事 ...

北 京 大 成 （ 成 都 ） 律 师 事 务 所 关 于 四 川 千 里 倍 益 康 医 疗 科 技 股 份 有 限 公 司 2024 年年度 股 东 会 的 法律意见书 大成蓉（2025）法意字第 1019 号 北 京 大 成 （ 成 都 ） 律 师 事 务 所 www.dentons.cn 四川省成都市高新区天府二街吉瑞五路 396 号金控时代广场 2 栋 邮编：610000 Building 2 of Financial Holding Times Square, No. 396 Jirui 5th Road,Tianfu 2nd Stree,High-tech Zone,Chengdu,China Tel: +8628-87039931 Fax: +8628-87036893 北京大成（成都）律师事务所 关于四川千里倍益康医疗科技股份有限公司 2024 年年度股东会的法律意见书 致：四川千里倍益康医疗科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司股东会规则》《上市公司 治理准则》《北京证券交易所股票上市规则》等法 ...

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 291 million yuan, with a net profit attributable to shareholders of 27.78 million yuan, and total assets of 690 million yuan as of December 31, 2024 [4] - The company's revenue decreased by 12.78% year-on-year, with domestic revenue dropping by 38.27% and overseas revenue increasing by 45% [10] - The net cash flow from operating activities in 2024 was approximately 29.99 million yuan, a decrease of 47% compared to 2023 [8] Group 2: Investment and Assets - In 2024, the company added fixed assets primarily for production equipment and to solidify its upstream supply chain, enhancing production capacity and efficiency [4] - The company currently holds 19 medical device registration certificates covering various fields such as electrotherapy and oxygen therapy [5] Group 3: Product Development and Innovation - The company has made significant progress in new product development, with several products receiving regulatory approval, including the portable pneumatic massage system, which has also passed FDA 510(k) review [4] - Future product plans include the development of various rehabilitation devices, with a goal to launch 7-8 new products annually [9] Group 4: Strategic Goals for 2025 - The company aims to expand its market presence internationally and enhance its product offerings through innovation and brand building [5][6] - Key operational goals include optimizing production processes, improving product quality, and reducing production costs to enhance profitability [6] Group 5: Brand and Market Positioning - The company is focused on reducing reliance on a single product, with the muscle massager accounting for 89.72% of main business revenue [12] - Strategies to enhance brand competitiveness include increasing brand awareness through advertising and improving product quality through continuous R&D investment [13] Group 6: Cost Control Measures - The company has implemented advanced production equipment and automated production lines to improve efficiency and reduce unit production costs [14] - Supply chain management has been optimized to ensure timely supply and stable quality of raw materials, thereby reducing procurement costs [14]

证券代码：870199 证券简称：倍益康 公告编号：2025-043 四川千里倍益康医疗科技股份有限公司 关于持股 5%以上股东及其一致行动人 权益变动触及 1%的提示性公告 1 | 股东名称 | 变动方式 | 减持股数 | 减持比例 | | --- | --- | --- | --- | | 千里致远 | 集中竞价 | 413,464 | 0.61% | | 千里志达 | 集中竞价 | 116,445 | 0.17% | 四川千里倍益康医疗科技股份有限（以下简称"公司"）于 2025 年 5 月 7 日 收到员工持股平台成都市千里致远企业管理中心（有限合伙）（以下简称"千里致 远"）和成都市千里志达企业管理中心（有限合伙）（以下简称"千里志达"）出具 的《股份减持进展告知函》，上述股东于 2025 年 5 月 6 日至 2025 年 5 月 7 日通 过集中竞价累计减持公司股份 529,909 股。 （二）本次权益变动前后，信息披露义务人及其一致行动人拥有上市公司权 益的股份情况： | 股东名称 | 股份性质 | 本次变动前持有股份 | | 本次变动后持有股份 | | | --- | --- | --- | ...

Group 1 - The company currently holds 19 medical device registration certificates covering various fields such as electrotherapy, oxygen therapy, physical therapy, and thermal therapy [2] - In 2024, the company launched new products including a bio-stimulation feedback device and a portable deep muscle massager, which received "Chengdu Industrial Boutique" certification, and has opened overseas markets with a pressure massage system certified by the US FDA [2] - New products such as medium frequency therapy devices, shortwave therapy devices, interference electric therapy devices, and pelvic floor rehabilitation therapy devices have obtained medical device registration certificates by early 2025, accelerating the commercialization process of the medical segment [2] Group 2 - The company emphasizes research and innovation, having successfully launched several market-demand-driven new products since its listing, including a variable amplitude deep muscle massager that has become a market hit due to its portability and diverse features [3] - The portable pressure massage system has gained recognition for its wireless design and comprehensive functional upgrades, making it an ideal choice for home and outdoor activities, receiving global user approval at the recent trade fair [3] - The company plans to continue launching home rehabilitation products such as therapy and moxibustion robots, aiming to cover health needs throughout the entire lifecycle, with a goal of developing 7-8 new products annually to maintain its leading position in the rehabilitation equipment sector [3]